Cellectis S.A.
CLLSHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeCellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of. The $326.3M market capitalization puts CLLS squarely in small-cap range for its industry. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Market Cap
$326.3M
Beta
2.77
P/E (TTM)
—
P/E (Fwd)
-5.23
EPS (TTM)
$-0.63
EPS (Fwd)
$-0.62
ROE
-94.5%
ROA
-11.7%
Cash
$166.7M
Total Debt
$80.3M
Free CF
$107.7M
52W Change
21.2%
Annual Financials
Cash vs Debt
Where CLLS stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, CLLS finished 0.87% below its 150-day moving average ($3.43) and 8.11% below its 200-day moving average ($3.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLLS overbought or oversold?
At the August 31, 2026 close, CLLS's RSI(14) was 66.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cellectis S.A. holds $166.7M in cash against $80.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $107.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -94.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $19.2M (2022) to $72.9M (2025), reflecting a 281% increase over the period.
With a beta above 1.5, CLLS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, CLLS has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing CLLS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.